Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global Endometrial Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Radiation Therapy, Surgery), By Enduser (Research Institutes, Hospitals & Clinics), & Pipeline Analysis, Outlook to 2023
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : May, 2017| No. of Pages : 100
Please make your selection :
Electronic Access - Single User License
US$ 2500.00
CD-ROM Mail Delivery
US$ 2700.00
Hard Copy Mail Delivery
US$ 2700.00
Electronic Access - Multi-User License
US$ 3500.00
List of Figures:
Figure 3-1: Estimated Age-specific Incidence & Mortality Rates for Endometrial Cancer, 2016
Figure 4-1: Endometrial Cancer Therapeutic Drugs - Mechanism of Action
Figure 5-1: Global Healthcare Spending (Billion US$), 2015 & 2020
Figure 5-2: Healthcare Spending by Region (Billion US$), 2015 & 2020
Figure 6-1: Global - Endometrial Cancer Therapeutics Market (Billion US$), 2016-2023
Figure 7-1: Global - Endometrial Cancer Therapeutics Market by Therapy (%), 2016
Figure 7-2: Global - Endometrial Cancer Chemotherapy Market (Billion US$), 2016 & 2023
Figure 7-3: Global - Endometrial Cancer Hormone Therapy Market (Billion US$), 2016 & 2023
Figure 7-4: Global - Endometrial Cancer Radiation Therapy Market (Billion US$), 2016 & 2023
Figure 7-5: Global - Endometrial Cancer Surgery Market (Billion US$), 2016 & 2023
Figure 7-6: Global - Endometrial Cancer Therapeutics Market by End Users (%), 2016
Figure 7-7: Global - Endometrial Cancer Therapeutics Market by Research Institutes (Billion US$), 2016 & 2023
Figure 7-8: Global - Endometrial Cancer Therapeutics Market by Hospitals (Billion US$), 2016 & 2023
Figure 7-9: Global - Endometrial Cancer Therapeutics Market by Geography (%), 2016
Figure 7-10: North America - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023
Figure 7-11: Europe - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023
Figure 7-12: Asia Pacific - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023
Figure 7-13: RoW - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023
Figure 8-1: Industrial Endometrial Cancer Therapeutic Drugs Pipeline by Clinical Phase (%), 2016
Figure 8-2: Research Pipeline Endometrial Cancer Therapeutic Drugs by Clinical Phase (%), 2016
Figure 11-1: Bayer AG - Net Sales Breakup by Business Segments (%), 2016
Figure 11-2: Bayer AG - Net Sales Breakup by Geography (%), 2016
Figure 11-3: F. Hoffman La Roche Ltd. - Revenue Breakup by Business Segments (%), 2016
Figure 11-4: Bristol-Myers Squibb Company - Revenue Breakup by Business Segments (%), 2016
Figure 11-5: Bristol-Myers Squibb Company - Revenue Breakup by Geography (%), 2016
Figure 11-6: Merck KGaA - Net Sales Breakup by Business Segments (%), 2016
Figure 11-7: Merck KGaA - Net Sales Breakup by Geography (%), 2016
Figure 11-8: Novartis AG - Net Sales Breakup by Business Segments (%), 2016
Figure 11-9: Novartis AG - Net Sales Breakup by Geography (%), 2016
Figure 11-10: Takeda Pharmaceutical Company Limited - Revenue Breakup by Geography (%), 2016
Figure 11-11: Eli Lilly and Company - Revenue Breakup by Products (%), 2016
Figure 11-12: Eli Lilly and Company - Revenue Breakup by Geography (%), 2016
Figure 11-13: Sanofi – Net Sales Breakup by Business Segments (%), 2016
Figure 11-14: Sanofi – Net Sales Breakup by Geography (%), 2016
Figure 11-15: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016
Figure 11-16: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016
List of Tables:
Table 6-1: Potential Patients for Endometrial Cancer Therapeutics, 2015, 2020 & 2025
Table 8-1: Industrial Endometrial Cancer Therapeutic Drugs Pipeline
Table 8-2: Research Collaborations Endometrial Cancer Therapeutic Drugs Pipeline
Table 10-1: Strategic Mergers & Collaborations in Endometrial Cancer Therapeutics Industry, 2014-2016
Table 11-1: Top Companies by Endometrial Cancer Therapeutic Drugs in Pipeline (2016)
Table 11-2: Bayer AG - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-3: Bayer AG - Key Financials (Million US$), 2014-2016
Table 11-4: F. Hoffman La Roche Ltd. - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-5: F. Hoffman La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 11-6: Bristol-Myers Squibb Company - Product Portfolio
Table 11-7: Bristol-Myers Squibb Company - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-8: Bristol-Myers Squibb Company - Key Financials (Million US$), 2014 - 2016
Table 11-9: Merck KGaA - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-10: Merck KGaA - Key Financials (Million US$), 2014-2016
Table 11-11: Novartis AG - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-12: Novartis AG - Key Financials (Million US$), 2014-2016
Table 11-13: Takeda Pharmaceutical Company Limited - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 11-15: Eli Lilly and Company - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-16: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
Table 11-17: Sanofi - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-18: Sanofi - Key Financials (Million US$), 2014-2016
Table 11-19: GlaxoSmithKline plc - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-20: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016
Table 11-21: ArQule, Inc. - Endometrial Cancer Therapeutic Drugs in Pipeline
Table 11-22: ArQule, Inc. - Key Financials (Million US$), 2014-2016
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact